Literature DB >> 21894149

Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice.

Ganna Tolstanova1, Xiaoming Deng, Samuel W French, William Lungo, Brankica Paunovic, Tetyana Khomenko, Amrita Ahluwalia, Tessa Kaplan, Maria Dacosta-Iyer, Andrzej Tarnawski, Sandor Szabo, Zsuzsanna Sandor.   

Abstract

The role of endothelial damage and increased vascular permeability (VP) in the pathogenesis of ulcerative colitis (UC) has not been investigated. We examined using functional, morphologic, and molecular biologic studies whether and to what extent the endothelial barrier dysfunction precedes enhanced epithelial permeability (EP) and the development of mucosal lesions during the early stages of experimental UC. We showed that in rats with iodoacetamide (IA)-induced UC increased colonic VP occurs early (ie, 2.6-fold increase at 15 min, P<0.01) preceding changes in epithelial barrier permeability. EP was unchanged at 15 and 30 min after IA administration and was increased 1.9-fold at 1 h and 6.7-fold at 2 h (both P<0.001) after IA. In the dextran sodium sulfate-induced slowly developing UC, colonic VP was significantly increased in 2 days (P<0.05) and EP only in 4 days (P<0.05). Mucosal endothelial injury led to hypoxia (P<0.05) of colonic surface epithelial cells 30 min after IA administration that was associated with increased expressions of transcription factors hypoxia-inducible factor-1α and early growth response-1. Electron and light microscopy demonstrated areas of colonic mucosa with perivascular edema covered by intact layer of surface epithelial cells in both rat and mouse models of UC. This is the first demonstration in four models of UC that endothelial damage, increased colonic VP, perivascular edema, and epithelial hypoxia precede epithelial barrier dysfunction that is followed by erosions, ulceration, and inflammation in UC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21894149     DOI: 10.1038/labinvest.2011.122

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

2.  Hemolysis-induced Lung Vascular Leakage Contributes to the Development of Pulmonary Hypertension.

Authors:  Olga Rafikova; Elissa R Williams; Matthew L McBride; Marina Zemskova; Anup Srivastava; Vineet Nair; Ankit A Desai; Paul R Langlais; Evgeny Zemskov; Marc Simon; Lawrence J Mandarino; Ruslan Rafikov
Journal:  Am J Respir Cell Mol Biol       Date:  2018-09       Impact factor: 6.914

3.  Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Ganna Tolstanova; Xiaoming Deng; Amrita Ahluwalia; Brankica Paunovic; Alona Prysiazhniuk; Lyudmyla Ostapchenko; Andrzej Tarnawski; Zsuzsanna Sandor; Sandor Szabo
Journal:  Dig Dis Sci       Date:  2015-05-14       Impact factor: 3.199

4.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

5.  Functional characterization of CXCR4 in mediating the expression of protein C system in experimental ulcerative colitis.

Authors:  Xuhong Lin; Huichao Wang; Yuxia Li; Jingnan Yang; Ruilin Yang; Dandan Wei; Junjie Zhang; Desheng Yang; Bin Wang; Xuequn Ren; Guanchang Cheng
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  Transient receptor potential vanilloid 4 channel regulates vascular endothelial permeability during colonic inflammation in dextran sulphate sodium-induced murine colitis.

Authors:  Kenjiro Matsumoto; Riho Yamaba; Ken Inoue; Daichi Utsumi; Takuya Tsukahara; Kikuko Amagase; Makoto Tominaga; Shinichi Kato
Journal:  Br J Pharmacol       Date:  2017-12-03       Impact factor: 8.739

Review 7.  Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.

Authors:  Dorota Cibor; Renata Domagala-Rodacka; Tomasz Rodacki; Artur Jurczyszyn; Tomasz Mach; Danuta Owczarek
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

8.  Establishment of a novel extracorporeal bowel model to study luminal approaches to treat inflammatory bowel disease.

Authors:  Anne Breitrück; Gisela Sparmann; Steffen Mitzner; Claus Kerkhoff
Journal:  Dis Model Mech       Date:  2013-08-14       Impact factor: 5.758

9.  Alkaline ceramidase 3 deficiency aggravates colitis and colitis-associated tumorigenesis in mice by hyperactivating the innate immune system.

Authors:  K Wang; R Xu; A J Snider; J Schrandt; Y Li; A B Bialkowska; M Li; J Zhou; Y A Hannun; L M Obeid; V W Yang; C Mao
Journal:  Cell Death Dis       Date:  2016-03-03       Impact factor: 8.469

10.  Oligomannan Prebiotic Attenuates Immunological, Clinical and Behavioral Symptoms in Mouse Model of Inflammatory Bowel Disease.

Authors:  Szilamér Ferenczi; Krisztián Szegi; Zsuzsanna Winkler; Teréz Barna; Krisztina J Kovács
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.